PE20080432A1 - Ciertas entidades quimicas, composiciones y metodos - Google Patents

Ciertas entidades quimicas, composiciones y metodos

Info

Publication number
PE20080432A1
PE20080432A1 PE2007000999A PE2007000999A PE20080432A1 PE 20080432 A1 PE20080432 A1 PE 20080432A1 PE 2007000999 A PE2007000999 A PE 2007000999A PE 2007000999 A PE2007000999 A PE 2007000999A PE 20080432 A1 PE20080432 A1 PE 20080432A1
Authority
PE
Peru
Prior art keywords
pyridyl
amino
substituted
phenyl
compositions
Prior art date
Application number
PE2007000999A
Other languages
English (en)
Inventor
Xiangping Qian
Jeffrey T Finer
Pu-Ping Lu
Chihyan Grace Chuang
Bradley P Morgan
Morgans
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of PE20080432A1 publication Critical patent/PE20080432A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA X, DONDE W1 ES N, CR6; W2 ES N, CR4, SIEMPRE QUE AMBOS W1 Y W2 NO SON N; R1 Y R4 SON CADA UNO H, CIANO, HALO, HIDROXI, AZIDO, ENTRE OTROS; Z1 ES H, ARILO SUSTITUIDO O NO, HETEROARILO, ENTRE OTROS; Z2 ES H, CARBOXILO, AMIDINO SUSTITUIDO O NO, ACILO, ENTRE OTROS; Z3 ES H, HALOGENO, ALQUILO SUSTITUIDO O NO; R3 ES H, ALQUILO SUSTITUIDO O NO; R6 ES H, ACILO, CIANO, HALO, AZIDO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-METIL-{6-FENIL-2-[(2-FENILETIL)AMINO]-(3-PIRIDIL)}CARBOXAMIDA; {2-[(3-METILBUTIL)AMINO]-6-FENIL-(3-PIRIDIL)}-N-(3-PIRIDILMETIL)CARBOXAMIDA; 2-{[(METILSULFONIL)AMINO]METIL}PIPERIDIL-6-FENIL-2-[(2-(2-PIRIDIL)ETIL)AMINO](3-PIRIDIL)CETONA; ENTRE OTROS. REFERIDA TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS MODULAN MIOSINA DEL MUSCULO LISO Y/O MIOSINA NO MUSCULAR UTILES EN EL TRATAMIENTO DE HIPERTENSION, ASMA, GLAUCOMA, DERRAME CEREBRAL, ENTRE OTROS
PE2007000999A 2006-08-01 2007-08-01 Ciertas entidades quimicas, composiciones y metodos PE20080432A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US83518306P 2006-08-01 2006-08-01
US83490406P 2006-08-01 2006-08-01
US83501006P 2006-08-01 2006-08-01
US83490306P 2006-08-01 2006-08-01
US83490106P 2006-08-01 2006-08-01
US83523606P 2006-08-02 2006-08-02

Publications (1)

Publication Number Publication Date
PE20080432A1 true PE20080432A1 (es) 2008-05-29

Family

ID=38997696

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000999A PE20080432A1 (es) 2006-08-01 2007-08-01 Ciertas entidades quimicas, composiciones y metodos

Country Status (4)

Country Link
AR (1) AR062176A1 (es)
PE (1) PE20080432A1 (es)
TW (1) TW200823188A (es)
WO (1) WO2008016643A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919511B2 (en) 2006-08-01 2011-04-05 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7932270B2 (en) 2006-08-01 2011-04-26 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7939534B2 (en) 2006-08-01 2011-05-10 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7939548B2 (en) 2006-08-02 2011-05-10 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP2202228B1 (en) * 2007-10-15 2014-12-10 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
JP2012529535A (ja) 2009-06-12 2012-11-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼモジュレーターとして有用なニコチンアミド化合物
ES2586856T3 (es) 2009-10-06 2016-10-19 Millennium Pharmaceuticals, Inc. Compuestos heterocíclicos útiles como inhibidores de PDK1
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
WO2015010832A1 (en) * 2013-07-22 2015-01-29 Syngenta Participations Ag Microbiocidal heterocyclic derivatives
JP2017214290A (ja) * 2014-09-12 2017-12-07 田辺三菱製薬株式会社 芳香族カルボン酸アミド化合物
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
GB201604970D0 (en) 2016-03-23 2016-05-04 Syngenta Participations Ag Improvements in or relating to organic compounds
MD3570834T2 (ro) 2017-01-11 2022-04-30 Alkermes Inc Inhibitori biciclici ai histon deacetilazei
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
WO2019032528A1 (en) 2017-08-07 2019-02-14 Rodin Therapeutics, Inc BICYCLIC HISTONE DEACETYLASE INHIBITORS
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
CN114929672A (zh) * 2019-11-06 2022-08-19 治疗方案股份有限公司 靶向癌症干细胞的癌症治疗
CN111393376B (zh) * 2020-05-11 2022-05-13 安徽赛迪生物科技有限公司 一种2-氯嘧啶-4-甲酸的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140853A (en) * 1975-04-18 1979-02-20 Schering Aktiengesellschaft Process for the preparation of aminopyridines
EP1740575A2 (en) * 2004-04-22 2007-01-10 Eli Lilly And Company Pyrrolidine derivatives useful as bace inhibitors

Also Published As

Publication number Publication date
TW200823188A (en) 2008-06-01
WO2008016643A2 (en) 2008-02-07
AR062176A1 (es) 2008-10-22
WO2008016643A3 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
PE20080432A1 (es) Ciertas entidades quimicas, composiciones y metodos
JP4663984B2 (ja) 疼痛の治療または防止に有用なチアジアゾリルピペラジン誘導体
TW200800899A (en) Novel compounds
WO2008002596A3 (en) Adenosine a2a receptor antagonists
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
BR122019017036B8 (pt) compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
SI1735278T1 (sl) Agenti histamin h receptorja priprava in terapevtska uporaba
JP2008513498A5 (es)
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
NZ547615A (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
BR0207526A (pt) Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
MX2012004848A (es) Compuestos heterociclicos triciclicos.
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
NO20092464L (no) Faste former av rasemisk ilaprazol
DK1750703T3 (da) Fremgangsmåde til at reducere gastrointestinal toksitet forårsaget af indgivelsen af tegafur
DE60230683D1 (de) 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
TW201605798A (zh) 新穎６－炔基吡啶
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
RU2450010C2 (ru) ЗАМЕЩЕННЫЕ ИМИДАЗО[2,1-b]ТИАЗОЛЫ И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ

Legal Events

Date Code Title Description
FC Refusal